T6962

Rasagiline Mesylate (AGN1135) is a novel MAO-B inhibitor, which can treat idiopathic Parkinson's disease.

TC-5115 is a highly potent, selective inhibitor of the SET domain of the histone lysine methyltransferase MLL1 (KMT2A), with an IC₅₀ value of 16 nM. TC-5115 exhibits weak inhibitory activity against other methyltransferases such as SET7/9, DOT1L, and EZH2 (IC₅₀ > 1 μM). TC-5115 induces differentiation and growth arrest in leukemia cells and can be used in leukemia research.

BIIE-0246 is a potent, selective and competitive non-peptide antagonist for the neuropeptide Y Y2 receptor. BIIE-0246 displays > 650-fold selectivity over Y1, Y4 and Y5 receptors.

Ritivixibat is an ileal bile acid transporter (IBAT) inhibitor and bile acid modulator. It is utilized in research related to cardiovascular diseases, fatty acid metabolism disorders, glucose utilization abnormalities, gastrointestinal conditions, and liver diseases.

Tridemorph is a sterol biosynthetic inhibitor. It is a fungicide used to control Erysiphe graminis. It was developed by BASF in the 1960s who use the trade name Calixin. The World Health Organization has categorized it as a Class II moderately hazardous" pesticide because it is believed harmful if swallowed and can cause irritation to skin and eyes."

Benitrobenrazide (Hexokinase 2 inhibitor 1) is a hexokinase 2 inhibitor with anticancer and antitumor activity.Benitrobenrazide inhibits the growth of tumors and can be used in cancer research.

L6H21 is an MD-2 inhibitor that can be used to study cognitive impairment and brain damage.

Iptacopan hydrochloride hydrate is a highly potent and highly selective factor B inhibitor.

Rasagiline-13C3 (mesylate) is intended for use as an internal standard for the quantification of rasagiline by GC- or LC-MS. Rasagiline (mesylate) (T6962) is an inhibitor of monoamine oxidase B (MAO-B; IC50= 4.43 nM for the rat brain enzyme).1It is selective for MAO-B over MAO-A (IC50= 412 nM for the rat brain enzyme). It inhibits serum and NGF withdrawal-induced apoptosis of PC12 cells when used at concentrations ranging from 0.01 to 100 μM.2Rasagiline inhibits rat brain MAO-Bin vivo (ED50= 0.1 mg/kg).1It reduces cerebral edema in a mouse model of traumatic brain injury.2Rasagiline (0.1 mg/kg) reduces cortical and hippocampal levels of full-length and soluble amyloid precursor protein (APP) in rats and mice. It also reduces α-synuclein-induced substantia nigral neuron loss and improves motor dysfunction in a mouse model of Parkinson's disease.3Formulations containing rasagiline have been used in the treatment of Parkinson's disease.